Abstract:Despite significant advances in the treatment of cutaneous melanoma (hereafter melanoma), the prognosis remains less favorable due to therapeutic resistance, which is presumably linked to epigenetic dysregulation. We hypothesized that the histone lysine demethylase KDM4B could play a pivotal role in controlling therapy‐resistant melanoma. To validate our hypothesis, we retrieved RNA sequencing data from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) program and observed upregulation of KDM4B in both primary and metastatic melanoma, which was associated with poor survival. To explore its role, we used murine B16, human SK‐MEL‐5, and G‐361 melanoma cells as in vitro models of melanoma. We found that KDM4B inhibition using NCGC00244536 increased global levels of H3K9me3 and downregulated the expressions of cell cycle progression–related genes Cdk1, Cdk4, Ccnb1, and Ccnd1. Moreover, genetic ablation of KDM4B or its chemical inhibition using NCGC00244536 reduced p53 production by upregulating MDM2, which enhances the proteolytic degradation of p53. Interestingly, despite the reduction of p53, these interventions augmented apoptosis and senescence‐induced cell death by activating pathways downstream of p53, as evidenced by reduced levels of pro‐survival Bcl‐2 and Bcl‐xL proteins and increased production of pro‐apoptotic cleaved caspase‐3, caspase‐7, Bax, and the senescence inducer Cdkn1a. Compared to the FDA‐approved anti‐melanoma agent dacarbazine, NCGC00244536 exhibited more pronounced cytotoxic and antiproliferative effects in melanoma cells. Importantly, NCGC00244536 demonstrated minimal cytotoxicity to low Kdm4b‐expressing mouse embryonic fibroblasts. In conclusion, our findings suggest that KDM4B inhibition can override the antitumor effect of p53, and potentially serve as a therapeutic strategy for melanoma.

KDM4A promotes malignant progression of breast cancer by down-regulating BMP9 inducing consequent enhancement of glutamine metabolism

Biological Roles of Human Bone Morphogenetic Protein 9 in the Bone Microenvironment of Human Breast Cancer MDA-MB-231 Cells.

BMP9 Regulates Cross-Talk Between Breast Cancer Cells and Bone Marrow-Derived Mesenchymal Stem Cells.

BMP9 Inhibits Proliferation and Metastasis of HER2-positive SK-BR-3 Breast Cancer Cells Through ERK1/2 and PI3K/AKT Pathways.

KDM4B down-regulation facilitated breast cancer cell stemness via PHGDH upregulation in H3K36me3-dependent manner

Epigenetic regulator KDM4A activates Notch1-NICD-dependent signaling to drive tumorigenesis and metastasis in breast cancer

BMP4 promotes the metastasis of gastric cancer by inducing epithelial-mesenchymal transition via Id1.

Histone Demethylase Lysine Demethylase 5B in Development and Cancer

BMP4 Promotes Hepatocellular Carcinoma Proliferation by Autophagy Activation Through JNK1-mediated Bcl-2 Phosphorylation

Bmp4 Enhances Hepatocellular Carcinoma Proliferation by Promoting Cell Cycle Progression Via Id2/Cdkn1b Signaling

KDM4B: A promising oncology therapeutic target

Data from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

BMP4 promotes metastasis of hepatocellular carcinoma by an induction of epithelial–mesenchymal transition via upregulating ID2

Additional File 2: Figure S1. of Aberrant KDM5B Expression Promotes Aggressive Breast Cancer Through MALAT1 Overexpression and Downregulation of Hsa-Mir-448

Tumor and Stem Cell Biology BMP 4 Administration Induces Differentiation of CD 133 þ Hepatic Cancer Stem Cells , Blocking Their Contributions to Hepatocellular Carcinoma

KDM4B facilitates colorectal cancer growth and glucose metabolism by stimulating TRAF6-mediated AKT activation

Histone 3 Lysine-27 Demethylase KDM6A Coordinates with KMT2B to Play an Oncogenic Role in NSCLC by Regulating H3K4me3

KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt/β-catenin signaling pathway

KDM6A Promotes Angiogenesis, Migration, and Invasion of Pancreatic Cancer by Activating LAMP3

BMP9 Promotes Autophagy and Inhibits Migration and Invasion in Breast Cancer Cells Through the C-Myc/snhg3/mtor Signaling Axis.

KDM4B Histone Demethylase Inhibition Attenuates Tumorigenicity of Malignant Melanoma Cells by Overriding the p53‐Mediated Tumor Suppressor Pathway